Artykuły w czasopismach na temat „Immune check point inhibitor”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Immune check point inhibitor”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Jaswani, Tamika S., Meeta Desai, Douglas Grider i Jonathan M. Bern. "Immune Check Point Inhibitor-induced Colitis". American Journal of Gastroenterology 112 (październik 2017): S858—S860. http://dx.doi.org/10.14309/00000434-201710001-01575.
Pełny tekst źródłaBobart, Shane A., Itunu Owoyemi, Joseph Grande, Nelson Leung i Sandra M. Herrmann. "Immune Check Point Inhibitor–Associated Endothelialitis". Kidney International Reports 5, nr 8 (sierpień 2020): 1371–74. http://dx.doi.org/10.1016/j.ekir.2020.05.027.
Pełny tekst źródłaAshour, Tarek, Georges Nakhoul, Pradnya Patil, Pauline Funchain i Leal Herlitz. "Immune Check Point Inhibitor–Associated Glomerulonephritis". Kidney International Reports 4, nr 2 (luty 2019): 355–59. http://dx.doi.org/10.1016/j.ekir.2018.10.017.
Pełny tekst źródłaKumar, Aswini, Maximilian Lee i Talhat Azemi. "IMMUNE CHECK POINT INHIBITOR MYOCARDITIS MIMICKING ACS". Journal of the American College of Cardiology 73, nr 9 (marzec 2019): 2681. http://dx.doi.org/10.1016/s0735-1097(19)33287-5.
Pełny tekst źródłaNilajgi, Shalini, Nicholas Kasmeridis i Kichendasse Ganessan. "A Case Of Immune Check Point Inhibitor - Induced Hypophysitis". Journal of the Endocrine Society 5, Supplement_1 (1.05.2021): A560. http://dx.doi.org/10.1210/jendso/bvab048.1142.
Pełny tekst źródłaSuchý, David. "Immune-related adverse events associated with immune check-point inhibitors". Klinická farmakologie a farmacie 33, nr 3 (28.10.2019): 20–24. http://dx.doi.org/10.36290/far.2019.019.
Pełny tekst źródłaMarthey, Lysiane, Raef Abdallah, Christophe Bellanger, Clément Bresteau, Antoine Meyer, Aurélien Amiot i Franck Carbonnel. "Immune check-point inhibitors related enterocolitis". Hépato-Gastro & Oncologie Digestive 30, nr 8 (październik 2023): 826–32. http://dx.doi.org/10.1684/hpg.2023.2641.
Pełny tekst źródłaJohncilla, Melanie, Shilpa Grover, Xuchen Zhang, Dhanpat Jain i Amitabh Srivastava. "Morphological spectrum of immune check‐point inhibitor therapy‐associated gastritis". Histopathology 76, nr 4 (18.02.2020): 531–39. http://dx.doi.org/10.1111/his.14029.
Pełny tekst źródłaKim, Jin Young, Chi Heum Cho i Hong Suk Song. "Targeted therapy of ovarian cancer including immune check point inhibitor". Korean Journal of Internal Medicine 32, nr 5 (1.09.2017): 798–804. http://dx.doi.org/10.3904/kjim.2017.008.
Pełny tekst źródłaVergne-Santiago, Norma, Ernesto Jos E. Sola Sanchez i Michelle Marie Mangual Garcia. "Immune Check Point Inhibitors Triggering Non Autoimmune Polyendocrinopathy". Journal of the Endocrine Society 5, Supplement_1 (1.05.2021): A136—A137. http://dx.doi.org/10.1210/jendso/bvab048.275.
Pełny tekst źródłaKorotaeva, A. A., N. V. Apanovich, E. A. Braga, V. B. Matveev i A. V. Karpukhin. "Current advances in kidney cancer immunotherapy". Cancer Urology 15, nr 4 (16.01.2020): 30–38. http://dx.doi.org/10.17650/1726-9776-2019-15-4-30-38.
Pełny tekst źródłaMaster, Samip R., Arelis Robinson, Glenn Morris Mills i Richard P. Mansour. "Cardiovascular complications of immune checkpoint inhibitor therapy." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): 2568. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.2568.
Pełny tekst źródłaDurno, Carol A., Melyssa Aronson, Melissa Edwards, Simon Ling, Valérie Larouche, Annika Bronsema, Michael Osborn i in. "Immune Check Point Inhibitor Treatment for Young Patients with Hypermutant Cancers". Gastroenterology 152, nr 5 (kwiecień 2017): S141. http://dx.doi.org/10.1016/s0016-5085(17)30801-6.
Pełny tekst źródłaAlbert, Stewart, Gouyu Ling, Srikanth Nadella i Aparna Yeggalam. "ODP170 Check Point Inhibitor Associated Multi-Endocrine Dysfunction Presenting With Euglycemic Ketoacidosis". Journal of the Endocrine Society 6, Supplement_1 (1.11.2022): A71—A72. http://dx.doi.org/10.1210/jendso/bvac150.148.
Pełny tekst źródłaKapoor, Vidit, i Olivier Rixe. "Toxicity of PD-1/CTLA-4 inhibitor immunotherapy among elderly patients." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): e14139-e14139. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14139.
Pełny tekst źródłaSchmidinger, Manuela, Irene Resch, Harun Fajkovic, Mesut Remzi, Shahrokh F. Shariat i Jens Bedke. "Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma?" Current Opinion in Urology 31, nr 3 (11.03.2021): 270–75. http://dx.doi.org/10.1097/mou.0000000000000874.
Pełny tekst źródłaThomas, Richard, Bibin Sebastian, Tom George, Noor Fatima Majeed, Temilola Akinola, Shawn L. Laferriere i Marta Braschi-Amirfarzan. "A review of the imaging manifestations of immune check point inhibitor toxicities". Clinical Imaging 64 (sierpień 2020): 70–79. http://dx.doi.org/10.1016/j.clinimag.2020.04.007.
Pełny tekst źródłaMbaraonye, Uchenne, Lily Romero Karam, Cindy Nguyen, Deepa Gotur i Simon Yau. "IMMUNE CHECK POINT INHIBITOR-INDUCED ORGANIZING PNEUMONIA IN A LUNG TRANSPLANT PATIENT". Chest 158, nr 4 (październik 2020): A1135—A1136. http://dx.doi.org/10.1016/j.chest.2020.08.1038.
Pełny tekst źródłaArcari, Luca, Giacomo Tini, Giovanni Camastra, Federica Ciolina, Domenico De Santis, Domitilla Russo, Damiano Caruso, Massimiliano Danti i Luca Cacciotti. "Cardiac Magnetic Resonance Imaging in Immune Check-Point Inhibitor Myocarditis: A Systematic Review". Journal of Imaging 8, nr 4 (5.04.2022): 99. http://dx.doi.org/10.3390/jimaging8040099.
Pełny tekst źródłaMathew Thomas, Vinay, Poorva Bindal, Swetha Ann Alexander i Kymberly McDonald. "Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor". Journal of Oncology Pharmacy Practice 26, nr 2 (25.03.2019): 459–61. http://dx.doi.org/10.1177/1078155219837342.
Pełny tekst źródłaDas, Undurti N. "Bioactive lipids as modulators of immune check point inhibitors". Medical Hypotheses 135 (luty 2020): 109473. http://dx.doi.org/10.1016/j.mehy.2019.109473.
Pełny tekst źródłaLleo, Ana, Lorenza Rimassa i Massimo Colombo. "Hepatotoxicity of immune check point inhibitors: Approach and management". Digestive and Liver Disease 51, nr 8 (sierpień 2019): 1074–78. http://dx.doi.org/10.1016/j.dld.2019.06.017.
Pełny tekst źródłaKiyota, Naomi. "Immune check point inhibitors for head and neck cancer". Toukeibu Gan 44, nr 4 (2018): 336–41. http://dx.doi.org/10.5981/jjhnc.44.336.
Pełny tekst źródłaSørensen, A. S., M. Nørgaard Andersen, K. Juul-Madsen, C. Skejø, H. Schmidt, T. Vorup-Jensen i T. W. Kragstrup. "OP0130 IN VITRO CHARACTERIZATION OF INFLAMMATORY ARTHRITIS ASSOCIATED WITH IMMUNE CHECK POINT INHIBITION". Annals of the Rheumatic Diseases 79, Suppl 1 (czerwiec 2020): 85.1–85. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1356.
Pełny tekst źródłaMudunov, A. M., A. V. Ignatova, A. S. Morozova, S. O. Podvyaznikov i Yu V. Alymov. "Combination of concurrent targeted and immune-therapy with nivolumab and cetuximab: new perspectives for squamous cell carcinoma treatment". Head and Neck Tumors (HNT) 10, nr 3 (16.11.2020): 111–17. http://dx.doi.org/10.17650/2222-1468-2020-10-3-111-117.
Pełny tekst źródłaElkayam, Natalie, i Shaurya Sharma. "Dual checkpoint inhibitor induced autoimmune encephalitis". Archive of Oncology 25, nr 2 (2019): 22–24. http://dx.doi.org/10.2298/aoo181230003e.
Pełny tekst źródłaTaylor, C., M. Reno i D. Sharma. "Secondary sclerosing cholangitis: a lesser known side effect of pembrolizumab therapy". American Journal of Clinical Pathology 156, Supplement_1 (1.10.2021): S123—S124. http://dx.doi.org/10.1093/ajcp/aqab191.263.
Pełny tekst źródłaIbraheim, Hajir, Esperanza Perucha i Nick Powell. "Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors". Rheumatology 58, Supplement_7 (1.12.2019): vii17—vii28. http://dx.doi.org/10.1093/rheumatology/kez465.
Pełny tekst źródłaDrommi, Fabiana, Alessia Calabrò, Grazia Vento, Gaetana Pezzino, Riccardo Cavaliere, Fausto Omero, Paola Muscolino i in. "Crosstalk between ILC3s and Microbiota: Implications for Colon Cancer Development and Treatment with Immune Check Point Inhibitors". Cancers 15, nr 11 (24.05.2023): 2893. http://dx.doi.org/10.3390/cancers15112893.
Pełny tekst źródłaKeyes, Erin, Muhammad B. Hammami i Kendall R. Beck. "2555 Immune Check Point Inhibitor Enteritis: A Case of Severe Duodenitis From Nivolumab Therapy". American Journal of Gastroenterology 114, nr 1 (październik 2019): S1405. http://dx.doi.org/10.14309/01.ajg.0000599752.28233.77.
Pełny tekst źródłaSanchez, Carlos A. Vergara, Rashid Alhusain, Jordan Christopher Ray i Julio Perez-Downes. "A CASE OF IMMUNE CHECK POINT INHIBITOR MEDIATED MYOPERICARDITIS: MANAGING A RARE ADVERSE REACTION". Journal of the American College of Cardiology 83, nr 13 (kwiecień 2024): 3204. http://dx.doi.org/10.1016/s0735-1097(24)05194-5.
Pełny tekst źródłaAlbarel, Frédérique, Frédéric Castinetti i Thierry Brue. "MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis". European Journal of Endocrinology 181, nr 3 (wrzesień 2019): R107—R118. http://dx.doi.org/10.1530/eje-19-0169.
Pełny tekst źródłaSoares, Adriana, Rafael Carmo, Catarina Rodrigues, Inês Teles Grilo i Enrique Grande. "Chemotherapy Plus Immune Check-Point Inhibitors in Metastatic Bladder Cancer". Bladder Cancer 6, nr 1 (28.03.2020): 1–8. http://dx.doi.org/10.3233/blc-190260.
Pełny tekst źródłaOrloff, Marlana, Ryan Weight, Matias E. Valsecchi i Takami Sato. "Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?" Reviews on Recent Clinical Trials 11, nr 2 (1.05.2016): 81–86. http://dx.doi.org/10.2174/1574887111666160330120712.
Pełny tekst źródłaKiyota, Naomi. "Current status of immune check point inhibitors for solid malignancy". Annals of Oncology 27 (listopad 2016): vii5. http://dx.doi.org/10.1093/annonc/mdw453.
Pełny tekst źródłaStruble, Roger, Vikas Koppurapu, Derek Hupp, Yana Zemkova, Andrei Schwartz, Jeff Wilson i Charles Rappaport. "YIELD OF BAL IN PATIENTS RECEIVING IMMUNE CHECK POINT INHIBITORS". Chest 158, nr 4 (październik 2020): A1935. http://dx.doi.org/10.1016/j.chest.2020.08.1675.
Pełny tekst źródłaGupta, Tarana, i Nikhil Sai Jarpula. "Hepatocellular carcinoma immune microenvironment and check point inhibitors-current status". World Journal of Hepatology 16, nr 3 (27.03.2024): 353–65. http://dx.doi.org/10.4254/wjh.v16.i3.353.
Pełny tekst źródłaM. Guirgis, Helmy. "The Impact of The Immune Check Point Duration of use on Cost in Lung Cancer". Pharmaceutics and Pharmacology Research 5, nr 6 (30.05.2022): 01–05. http://dx.doi.org/10.31579/2693-7247/086.
Pełny tekst źródłaChintalacheruvu, Lakshmi Manogna, Kushal Naha, Vamsi Krishna Chilluru i Donald C. Doll. "Review of neurological side effects associated with checkpoint inhibitor therapy in cancer patients." Journal of Clinical Oncology 38, nr 5_suppl (10.02.2020): 72. http://dx.doi.org/10.1200/jco.2020.38.5_suppl.72.
Pełny tekst źródłakazuhiro, S., K. Sugiyama, K. Nozawa, Y. Funahashi, Y. Kogure, C. Kitagawa, S. Ichihara, R. Nishimura, T. Kubota i H. Saka. "Single-institute, retrospective study of metastatic uveal melanoma in the immune check point inhibitor era". Annals of Oncology 29 (listopad 2018): ix106. http://dx.doi.org/10.1093/annonc/mdy439.005.
Pełny tekst źródłaMalkova, A. M., R. V. Orlova, N. V. Zhukova, A. R. Gubal i V. V. Sharoiko. "Analysis of possible markers of effective antitumor cellular immune response before starting therapy with immune check-point inhibitors". Siberian journal of oncology 21, nr 2 (8.05.2022): 109–17. http://dx.doi.org/10.21294/1814-4861-2022-21-2-109-117.
Pełny tekst źródłaRevathi, Duraisamy, Ganapathy Dhanraj i V. Ashok. "Immune check point inhibitors: A promising therapeutic approach in oral cancer". Oral Oncology 132 (wrzesień 2022): 105977. http://dx.doi.org/10.1016/j.oraloncology.2022.105977.
Pełny tekst źródłaKhamnueva, L. Yu Khamnueva, K. A. Sergeeva Sergeeva, L. S. Andreeva Andreeva i A. V. Davydova Davydova. "Endocrinopathies induced by immune check point inhibitors. Optimal patient management tactics". Pharmateca 12_2020 (23.11.2020): 8–13. http://dx.doi.org/10.18565/pharmateca.2020.12.8-13.
Pełny tekst źródłaStringer, Bryan F., Nikhila Kethireddy, Alain Rizkallah i Konstadina Darsaklis. "MYOCARDITIS SECONDARY TO IMMUNE CHECK-POINT INHIBITORS: DIFFICULTIES IN ARRHYTHMIA MANAGEMENT". Journal of the American College of Cardiology 75, nr 11 (marzec 2020): 2694. http://dx.doi.org/10.1016/s0735-1097(20)33321-0.
Pełny tekst źródłaMuhailan, Mohamad, i Ghassan Al-Shbool. "Pseudo-Wellens’ Syndrome Temporally Associated With Immune Check Point Inhibitors Use". American Journal of the Medical Sciences 359, nr 1 (styczeń 2020): e1-e2. http://dx.doi.org/10.1016/j.amjms.2019.07.006.
Pełny tekst źródłaKim, Hyunseok, Soyeon Ahn, Hyungjin Kwon, Hsuan-Ju Chen, Inwon Park, Pilhan Kim i Akyildiz Kubra. "Abstract 2397: An advanced approach technique for tracking point between immune check point inhibitor and cancer cell mechanism in immune response motility by infiltration a breast cancer cell". Cancer Research 83, nr 7_Supplement (4.04.2023): 2397. http://dx.doi.org/10.1158/1538-7445.am2023-2397.
Pełny tekst źródłaRoy, Arya Mariam, i Saby George. "Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena". Cancer Drug Resistance 6, nr 3 (20.09.2023): 642–55. http://dx.doi.org/10.20517/cdr.2023.47.
Pełny tekst źródłaFurnish, Robin, Heather Bear, Xin Wei i Timothy Phoenix. "MODL-29. EVALUATING TUMOR-IMMUNE INTERACTIONS IN MOUSE MODELS OF DIFFUSE INTRINSIC PONTINE GLIOMA". Neuro-Oncology 22, Supplement_3 (1.12.2020): iii417. http://dx.doi.org/10.1093/neuonc/noaa222.602.
Pełny tekst źródłaDe Felice, Francesca, Daniela Musio i Vincenzo Tombolini. "Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment". Journal of Personalized Medicine 11, nr 5 (10.05.2021): 393. http://dx.doi.org/10.3390/jpm11050393.
Pełny tekst źródłaKikuchi, Yoshihiro, Hiroko Kouta, Takayoshi Asakawa, Miyuki Horikoshi, Tomoyuki Yoshikawa, Masashi Takano i Kenichi Furuya. "Roles of an immune-check point inhibitor (nivolumab) in heavily pretreated and platinum-resistant gynecologic cancers." Journal of Clinical Oncology 36, nr 15_suppl (20.05.2018): e17562-e17562. http://dx.doi.org/10.1200/jco.2018.36.15_suppl.e17562.
Pełny tekst źródła